Genentech Xanelim, Biogen Amevive Pivotal Trial Data In Psoriasis Presented
This article was originally published in Pharmaceutical Approvals Monthly
A second course of treatment with Genentech and Xoma’s monoclonal antibody Xanelim (efalizumab) resulted in an additional 20% of psoriasis patients achieving the primary efficacy endpoint, according to data from a pivotal trial presented June 21 at the 2nd Joint Meeting of the International Psoriasis Symposium and European Congress on Psoriasis.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class